A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing

Trial Profile

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor
  • Indications Acute coronary syndromes; Coronary artery disease; Stroke
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Oct 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 11 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 12 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top